Zenas Biopharma Inc.
D

ZBIO

27.540
USD
0.64
(2.38%)
مفتوح الان
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
7,153
الربح لكل سهم
-6
العائد الربحي
-
P/E
-3
حجم السوق
1,794,966,951
نظرة عامة
أصول ذات صلة
BBH
BBH
D
VanEck Biotech ETF
246.572
-1.835(-0.74%)
246.750+0.179(+0.07%)
BIB
BIB
D
ProShares Ultra Nasdaq Biotechnology
110.320
-2.526(-2.24%)
110.410+0.090(+0.08%)
IBB
IBB
D
iShares Biotechnology ETF
207.740
-1.800(-0.86%)
207.7400.000(0.00%)
IHE
IHE
D
iShares US Pharmaceuticals ETF
102.510
-2.270(-2.17%)
102.5100.000(0.00%)
LABD
LABD
D
Direxion Daily S&P Biotech Bear 3X Shares
7.96000
0.34000(4.46%)
7.960000.00000(0.00%)
LABU
LABU
D
Direxion Daily S&P Biotech Bull 3X Shares
219.600
-9.580(-4.18%)
219.6000.000(0.00%)
PPH
PPH
D
VanEck Pharmaceutical ETF
114.930
-2.110(-1.80%)
114.9300.000(0.00%)
XBI
XBI
D
SPDR S&P Biotech ETF
149.540
-2.100(-1.38%)
149.800+0.260(+0.17%)
المزيد

العنوان: Zenas Biopharma Inc.

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.